

## State of Oklahoma Oklahoma Health Care Authority Talzenna® (Talazoparib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy billing (NDC:	) Start Date (or date of next dose):	
Dose:	Regimen:	
Billing Provider Information		
Provider NPI:	Provider NPI: Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
B. Human epiderma C. Positive test for B D. Hormone recepto i. If yes, has me endocrine thera E. Hormone recepto F. Does member ha G. Will talazoparib be  Other, please provid Additional Information:	apy? Yes No or (HR)-negative? Yes No ve symptomatic visceral disease? Y e used as a single agent? Yes le diagnosis:	No or considered to not be a candidate for es No No
If yes, please specify adverse re	dence of progressive disease while of diverse drug reactions related to tala eactions:	
best of my knowledge.	and the mountainy moodboary and	

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

result in processing delays.

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.